Ion channelopathies: A tapped-out mine?

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 3, 2011, Pages

  Dudley Jr , Samuel C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; FLECAINIDE; SODIUM CHANNEL BLOCKING AGENT; VOLTAGE GATED SODIUM CHANNEL;

ACTION POTENTIAL; ARTICLE; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CATECHOLAMINERGIC SYSTEM; CHANNELOPATHY; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; MUSCLE CELL; PRIORITY JOURNAL; REPOLARIZATION;

CHANNELOPATHIES; GENOTYPE; HUMANS; ION CHANNELS; LONG QT SYNDROME; MUTATION; PHENOTYPE;

EID: 79955055693     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01281.2010     Document Type: Article

References (10)

1. Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature 376: 683-685, 1995.
2. 2+ regulation. Heart Rhythm 6: 1652-1659, 2009.
3. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80: 795-803, 1995.
4. + current and potentiates ranolazine inhibition of Nav1.5 channels. Am J Physiol Heart Circ Physiol 300: H288-H299, 2011. doi:10.1152/ajpheart.00539.2010.
5. Kaufman ES. Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. Heart Rhythm 6: S51-S55, 2009.
6. + current regulation by pyridine nucleotides. Circ Res 105: 737-745, 2009.
7. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest 115: 2025-2032, 2005.
8. Sicouri S, Antzelevitch D, Heilmann C, Antzelevitch C. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome. J Cardiovasc Electrophysiol 8: 1280-1290, 1997.
9. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15: 380-383, 2009.
10. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 100: 1660-1666, 1999.